If you have been reading about prothymosin alpha and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Although the agreement was rejected in the subsequent October plebiscite, the same month, then-president of Colombia Juan Manuel Santos was awarded the Nobel Peace Prize for his efforts to bring the country's more than 50-year-long civil war to an end. A revised peace deal was signed the following month and submitted to Congress for approval. The House of Representatives unanimously approved the plan on November 30, a day after the Senate gave its backing.
== Honors and awards == Independent Scientist Research (K02) Award, National Institute of Mental Health, 2002–2007. Fellow, Association for Psychological Science, 2003. Fellow, Society for Personality and Social Psychology, 2005. Fellow, American Psychological Association, 2005. Career Trajectory Award, Society of Experimental Social Psychology, 2006. Cattell Fund Fellowship, 2007–2008. NIH Director's Pioneer Award, 2007–2012, to study how the brain creates emotion. Kavli Fellow, National Academy of Sciences, 2008. Elected Fellow, American Association for the Advancement of Science, 2008. Arts in Academics award, University of Waterloo, 2010. Excellence in Research and Creative Activity Award, Northeastern University, 2012. Elected Fellow, Royal Society of Canada, 2012. Award for Distinguished Service in Psychological Science, American Psychological Association, 2013. Elected Fellow, Society of Experimental Psychologists, 2013. Diener Award in Social Psychology, Society for Personality and Social Psychology, 2014. Heritage Wall of Fame, Foundation for Personality and Social Psychology, 2016. Mentor Award for Lifetime Achievement, Association for Psychological Science, 2018. Elected Fellow, American Academy of Arts and Sciences, 2018. President, Association for Psychological Science, 2019–2020. Guggenheim Fellowship in neuroscience, 2019. John P. McGovern Award in the Behavioral Sciences, American Association for the Advancement of Science, 2020. APA Award for Distinguished Scientific Contributions, American Psychological Association, 2021.
In practice, the solid support is used in excess (often tenfold) to be sure that all expected components are formed. The above limitation is completely removed if the solid support is omitted and the synthesis is carried out in solution. In this case, there is no upper limit concerning the number of components of the library. Both the number of components and the quantity of the library can be freely decided based only on practical considerations. An important modification was introduced in the synthesis of DNA encoded combinatorial libraries by Harbury and Halpin. The solid support in their case is replaced by the encoding DNA oligomers. This makes it possible to synthesize libraries containing even trillions of components and screen them using affinity binding methods. A different way of carrying out solution-phase S&P synthesis is applying scavenger resins to remove the byproducts. Scavenger resins are polymers having functional groups that make it possible to react with and bind components of the excess of reagents then filtered them out from the reaction mixture Two examples: a resin containing primary amino groups can remove the excess of acyl chlorides from reaction mixtures while an acyl chloride resin removes amines. A fluorous technology was described by Curran The fluorous synthesis employs functionalized perfluoroalkyl (Rf) groups like 4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluorononyl {CF3(CF2)4CF2CH2CH2-} group attached to substrates or reagents. The Rf groups make it possible to remove either the product or the reagents from the reaction mixture.
Sources: en.wikipedia.org
In a letter to Crick on 11 December 1954, discussing how RNA could be produced from DNA since they contain fundamentally similar nucleotide compositions, he wrote: "I suspect the answer is staring us in the face." To solve the riddle of protein synthesis, Gamow (as the Synthesiser) created an informal team of scientists which he called the RNA Tide Club in 1954. As his prediction to denote 20 amino acids, the club could have only 20 members, with the designated officers: Crick (as the Pessimist), Rich (the Lord Privy Seal) and Watson (the Optimist) among them. It was meant partly to be humorous.
=== Early life and education === Kimon Georgiev Stoyanov was born on 11 August 1882 in the town of Tatar Pazardzhik, then part of Eastern Rumelia, into a middle-class family. He was nicknamed "The Greek" because his mother was of Greek descent. His paternal grandfather, called Stoyan Balkachiyata, moved to the town from the village of Debrashtitsa in the early 19th century. His father was Georgi Stoyanov Krustyov, born around 1848. His maternal grandfather was Todor Bogdanov, who came to Pazardzhik from the village of Kalugerovo. His mother was Maria Bogdanova-Abadzhieva, born around 1858. He had an older brother and sister, so he was the youngest child in his family. At the time, his father died of tuberculosis only three months after his birth. He graduated primary education in Pazardzhik in 1897. He was firstly interested in engineering, but his family couldn't afford to study abroad, so they later directed him into starting his military career, where he was accepted into the Military University in Sofia.
The three substrates of this enzyme are L-phenylalanine, water, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are phenylpyruvic acid, ammonia, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-phenylalanine:NAD+ oxidoreductase (deaminating). Other names in common use include L-phenylalanine dehydrogenase, and PHD. This enzyme participates in phenylalanine metabolism and phenylalanine, tyrosine and tryptophan biosynthesis.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.